Loading stock data…
Monopar Therapeutics Inc (MNPR)
$94.56+6.88 (+7.85%)
After Hours$94.56+0.00 (+0.00%)· Last close Jun 29
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Monopar Therapeutics Inc. in the Healthcare sector is trading at $94.56 with a market capitalization of $419M. Wall Street consensus targets $112.62 (13 analysts), implying a +19.1% move over the next 12 months. The stock is currently near its 52-week high of $105.00, remaining 39.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +19.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.23M↑ | -$6.16M↓ | -$4.09M↓ | -$3.23M↓ | -$3.22M |
| Net Income | -$3.89M↑ | -$5.20M↓ | -$3.44M↓ | -$2.45M↑ | -$2.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNP...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$419.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.07%
Volume
Today's trading volume
119,351
Recent News
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.
Key Insights Institutions' substantial holdings in Monopar Therapeutics implies that they have significant influence...
Broadcom Stock Sees Improved Relative Strength Rating
In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Broadcom Stock A Buy?
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.